Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page
- Check5 days agoChange DetectedExpanded the study site locations with a broader set of recruitment sites across the United States and worldwide, and removed several previously listed locations.SummaryDifference4%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedFooter revision label updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check34 days agoChange DetectedAdded notes clarifying that publications can be entered voluntarily and may be auto-filled from PubMed; a revision label v3.3.1 was added, replacing the former v3.2.0 wording.SummaryDifference0.2%

- Check41 days agoChange DetectedRemoved the government funding status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check56 days agoChange DetectedThe Study Details page appears unchanged between screenshots; there are no alterations to the trial title, interventions, outcomes, or eligibility criteria.SummaryDifference0.1%

- Check84 days agoChange DetectedMajor update: region name updated from Rhone-Alpes to Auvergne-Rhône-Alpes with a new Pierre-Bénite entry; page version bumped to v3.2.0; added government operating-status notice.SummaryDifference3%

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.